CAMP (Camp4 Therapeutics) Total Operating Expense: $56.60 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAMP Camp4 Therapeutics Corp CAMP
8 GF Score
Price $4.49
! 4 Warning Signs
View Full Analysis

What is Camp4 Therapeutics Total Operating Expense?

Camp4 Therapeutics CAMP +0.67% 8 Total Operating Expense is $56.60 Mil as of Jun. 2026. GuruFocus rates CAMP with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Camp4 Therapeutics's Total Operating Expense for the three months ended in Jun. 2026 was $15.16 Mil. Camp4 Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was $56.60 Mil.

Camp4 Therapeutics Total Operating Expense Related Terms

Camp4 Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Camp4 Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camp4 Therapeutics Total Operating Expense Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Operating Expense
45.00 52.23 53.74 55.56

Camp4 Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.53 13.95 13.12 14.37 15.16
CAMP
8GF Score
Camp4 Therapeutics Corp CAMP
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camp4 Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $56.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $56.60 Mil mean?
Camp4 Therapeutics (CAMP) has a Total Operating Expense of $56.60 Mil as of Jun. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Camp4 Therapeutics and its competitors.
Is Camp4 Therapeutics' Total Operating Expense too high?
Camp4 Therapeutics' current Total Operating Expense is $56.60 Mil. Overall, Camp4 Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Camp4 Therapeutics' Total Operating Expense compare to ALEC and ORMP?
Camp4 Therapeutics' Total Operating Expense of $56.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Camp4 Therapeutics and its competitors. Camp4 Therapeutics's current Total Operating Expense is $56.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camp4 Therapeutics stock overvalued right now?
Camp4 Therapeutics (CAMP) has a current Total Operating Expense of $56.60 Mil. The current Total Operating Expense is $56.60 Mil. Camp4 Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Camp4 Therapeutics (CAMP), the current Total Operating Expense is $56.60 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Camp4 Therapeutics Business Description

Address One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA, 02139
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
8GF Score

Get the complete analysis for CAMP

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.49
Price